Bristol-Myers Squibb Company
$ 59.02
0.37%
23 Apr - close price
- Market Cap 120,503,222,000 USD
- Current Price $ 59.02
- High / Low $ 59.25 / 58.64
- Stock P/E 17.06
- Book Value 9.07
- EPS 3.46
- Next Earning Report 2026-04-30
- Dividend Per Share $2.49
- Dividend Yield 4.23 %
- Next Dividend Date 2026-05-01
- ROA 0.10 %
- ROE 0.40 %
- 52 Week High 62.25
- 52 Week Low 41.46
About
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Analyst Target Price
$63.04
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-10-30 | 2025-07-31 | 2025-04-24 | 2025-02-06 | 2024-10-31 | 2024-07-26 | 2024-04-25 | 2024-02-02 | 2023-10-26 | 2023-07-27 | 2023-04-27 |
| Reported EPS | 1.26 | 1.63 | 1.46 | 1.8 | 1.67 | 1.8 | 2.07 | -4.4 | 1.59 | 2 | 1.75 | 2.05 |
| Estimated EPS | 1.63 | 1.69 | 1.1 | 1.5 | 1.47 | 1.5 | 1.63 | -4.14 | 1.43 | 1.76 | 1.98 | 1.97 |
| Surprise | -0.37 | -0.06 | 0.36 | 0.3 | 0.2 | 0.3 | 0.44 | -0.26 | 0.16 | 0.24 | -0.23 | 0.08 |
| Surprise Percentage | -22.6994% | -3.5503% | 32.7273% | 20% | 13.6054% | 20% | 26.9939% | -6.2802% | 11.1888% | 13.6364% | -11.6162% | 4.0609% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.45 |
| Currency | USD |
Previous Dividend Records
| May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-05-01 | 2026-02-02 | 2025-11-03 | 2025-08-01 | 2025-05-01 | 2025-02-03 | 2024-11-01 | 2024-08-01 | 2024-05-01 | 2024-02-01 |
| Amount | $0.63 | $0.63 | $0.62 | $0.62 | $0.62 | $0.62 | $0.6 | $0.6 | $0.6 | $0.6 |
Next Dividend Records
| Dividend per share (year): | $2.49 |
| Dividend Yield | 4.23% |
| Next Dividend Date | 2026-05-01 |
| Ex-Dividend Date | 2026-04-02 |
Recent News: BMY
2026-04-24 12:07:13
Bristol Myers Squibb and Pfizer have announced a collaboration with Mark Cuban Cost Plus Drug Company to make Eliquis (apixaban), a widely prescribed oral blood thinner, available on CostPlusDrugs.com starting April 27, 2026. This initiative aims to expand access and reduce costs for cash-paying patients, who will be able to purchase a 30-day supply for $345. The move is part of the BMS-Pfizer Alliance's commitment to transparency and addressing access barriers for important medications.
2026-04-24 10:59:09
Bristol Myers Squibb and Pfizer have partnered with Mark Cuban Cost Plus Drug Company to make Eliquis (apixaban) available on CostPlusDrugs.com starting April 27, 2026. This initiative aims to provide cash-paying patients with a more affordable and transparent way to access the oral blood thinner, which will cost $345 for a 30-day supply. Eliquis is widely prescribed to reduce the risk of stroke and blood clots in patients with atrial fibrillation and to treat deep vein thrombosis and pulmonary embolism.
2026-04-24 07:37:11
Ardelyx, a US biopharma company, has appointed Felecia Ettenberg as its new chief legal officer, succeeding the retiring Elizabeth Grammer. Ettenberg brings nearly 25 years of experience from Bristol Myers Squibb, where she held various legal roles, including deputy general counsel. In her new position, she will oversee Ardelyx's legal, compliance, regulatory, and government affairs functions to support the company's growth strategy and commitment to patients.
2026-04-24 02:34:09
Bristol-Myers Squibb (BMY) has seen a 27% rally over the last year, prompting questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 51.5%, while its P/E ratio also indicates it is undervalued compared to a proprietary "Fair Ratio." The article provides bull and bear case narratives, with fair value anchors ranging from US$45.67 to US$65.00 per share, offering investors different perspectives for their decision-making.
2026-04-23 21:40:09
DelveInsight's report highlights that over 80 pharmaceutical companies are actively developing novel therapies for Idiopathic Pulmonary Fibrosis (IPF), with Bristol-Myers Squibb's LPA1 antagonist, BMS-986278, currently in Phase III. The pipeline includes diverse approaches from companies like Genentech, Tvardi Therapeutics, and Melius Pharma, targeting various mechanisms such as inflammation, fibrosis, and associated symptoms like chronic cough. The U.S. FDA's recent approval of Boehringer Ingelheim's JASCAYD signifies a significant advancement for IPF patients, while ongoing research promises further therapeutic breakthroughs.
2026-04-23 19:26:16
Former U.S. President Donald Trump announced that Regeneron has agreed to offer its prescriptions at "most favored nation" prices. This move aims to potentially lower drug costs, aligning with previous efforts to reduce pharmaceutical expenditures. The announcement comes as part of broader discussions around healthcare pricing in the United States.
